Research programme: anti-CD40 agonistic antibodies - Biopharma
Latest Information Update: 28 Aug 2023
At a glance
- Originator Biopharma
- Developer Biopharma; Twist Bioscience
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action CD40 antigen stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer